

Design of an α -helical antimicrobial peptide with improved cell-selective and potent anti-biofilm activity

Shi-Kun Zhang¹, Jin-wen Song¹, Feng Gong¹, Su-Bo Li¹, Hong-Yu Chang², Hui-Min Xie³,
Hong-Wei Gao ^{*1}, Ying-Xia Tan^{*1}, Shou-Ping Ji^{*1}

1. Department of Tissue Engineering, Beijing Institute of Transfusion Medicine, Beijing, China.
2. Department of Paediatrics, General Hospital of the PLA Rocket Force, Beijing, China.
3. Department of Rehabilitation Center, General Hospital of the PLA, Beijing, China.

*Correspondence to: Shou-Ping Ji, Ying-Xia Tan and Hong-Wei Gao, Department of Tissue Engineering, Beijing Institute of Transfusion Medicine, 27 Taiping Road, Beijing 100850, China. E-mail: jishouping@yahoo.com; tuanhu333@126.com; gaohongwei1976@126.com




Figure S1 Determination of the secondary structures of peptide in water (dashed line), 30 μ M SDS (solid line) and 50% TFE (dotted line).




Figure S2 Determination of the secondary structures of melittin and M(G1R, V8R, I17R) in water (dashed line), 30 μ M SDS (solid line) and 50%TFE (dotted line).




Figure S3 Toxicity activity of melittin and M(G1R, V8R, I17R). (a). Haemolysis activity of melittin and M(G1R, V8R, I17R) against hrBC. (b). Toxicity activity of melittin and M(G1R, V8R, I17R) against L929.

Table S1

| Peptide | Sequence |
|-------------------|--|
| Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ.NH ₂ |
| M(G1R, V8R, I17R) | RIGAVLKRLTTGLPALK SWIKRKRQQ.NH ₂ |

Table S2

| Peptides | MIC (μM) ^a | | | GM ^b | MHC ^c | TI ^d | Fold |
|-------------------|------------------------------------|---------------------|---------------------|-------------------|-------------------|-----------------|------|
| | <i>E.coli</i> | <i>P.aeruginosa</i> | <i>K.pneumoniae</i> | (μM) | (μM) | | |
| RV-23 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 1 | |
| melittin | 12.5 | 6.25 | 6.25 | 7.87 | 0.78 | 0.1 | 1 |
| M(G1R, V8R, I17R) | 25 | 25 | 12.5 | 19.8 | 200 | 10.1 | 101 |

^a Minimum inhibitory concentrations (MIC) were determined as the lowest concentration of peptide that prevented visible turbidity.

^b The geometric mean (GM) of the peptide MICs against all four bacterial strains was calculated.

^c MHC is the minimum hemolytic concentration that caused 10% hemolysis of human red blood cells (hRBC). When no detectable hemolytic activity was observed at 100 μM , a value of 200 μM was used to calculate the therapeutic index.

^d Therapeutic index (TI) is the ratio of the MHC to the geometric mean of MIC (GM). Larger values indicate greater cell selectivity.

Table S3

| Peptides | MIC (μM) ^a | | | GM ^b (μM) | MHC ^c (μM) | TI ^d | Fold |
|-------------------|------------------------------------|-----------------------|--------------------|--------------------------------------|---------------------------------------|-----------------|------|
| | <i>S. aureus</i> | <i>S. epidermidis</i> | <i>B. subtilis</i> | | | | |
| RV-23 | 12.5 | 3.125 | 3.125 | 4.96 | 6.25 | 1.26 | |
| melittin | 3.125 | 3.125 | 3.125 | 3.13 | 0.78 | 0.25 | 1 |
| M(G1R, V8R, I17R) | 100 | 6.25 | 3.125 | 12.5 | 200 | 16 | 64 |

^a Minimum inhibitory concentrations (MIC) were determined as the lowest concentration of peptide that prevented visible turbidity.

^b The geometric mean (GM) of the peptide MICs against all four bacterial strains was calculated.

^c MHC is the minimum hemolytic concentration that caused 10% hemolysis of human red blood cells (hRBC). When no detectable hemolytic activity was observed at 100 μM , a value of 200 μM was used to calculate the therapeutic index.

^d Therapeutic index (TI) is the ratio of the MHC to the geometric mean of MIC (GM). Larger values indicate greater cell selectivity.